MEDNAX (NYSE:MD) Lowered to Neutral at Citigroup – Riverton Roll

MEDNAX (NYSE:MD) was downgraded by equities research analysts at Citigroup from a buy rating to a neutral rating in a research report issued on Friday, January 3rd, Marketbeat Ratings reports. They presently have a $29.00 price target on the stock. Citigroups price objective points to a potential upside of 4.73% from the stocks current price.

Several other equities research analysts have also recently weighed in on the stock. TheStreet cut shares of MEDNAX from a c- rating to a d rating in a research report on Friday, November 1st. Bank of America cut shares of MEDNAX from a neutral rating to an underperform rating and set a $19.00 target price for the company. in a research report on Friday, September 6th. ValuEngine raised shares of MEDNAX from a sell rating to a hold rating in a research report on Friday, January 3rd. JPMorgan Chase & Co. increased their target price on shares of MEDNAX from $26.00 to $33.00 and gave the company a neutral rating in a research report on Friday, December 20th. Finally, SunTrust Banks increased their target price on shares of MEDNAX from $27.00 to $30.00 and gave the company a hold rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $27.33.

Shares of NYSE:MD opened at $27.69 on Friday. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 7.89, a PEG ratio of 1.03 and a beta of 0.78. MEDNAX has a 12 month low of $19.93 and a 12 month high of $38.88. The firms 50-day moving average is $27.00 and its 200 day moving average is $24.24. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 1.35.

MEDNAX (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.83 by $0.08. The company had revenue of $888.70 million for the quarter, compared to the consensus estimate of $876.20 million. MEDNAX had a negative net margin of 40.86% and a positive return on equity of 10.38%. The firms revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.94 EPS. As a group, equities analysts forecast that MEDNAX will post 3.03 EPS for the current fiscal year.

In other news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $22.88, for a total value of $114,400.00. Following the sale, the director now owns 10,821 shares in the company, valued at $247,584.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.40% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in MD. Benjamin F. Edwards & Company Inc. grew its position in MEDNAX by 56.2% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 1,773 shares of the companys stock valued at $40,000 after buying an additional 638 shares during the period. Parallel Advisors LLC grew its position in shares of MEDNAX by 78.4% in the third quarter. Parallel Advisors LLC now owns 1,993 shares of the companys stock valued at $45,000 after purchasing an additional 876 shares during the period. US Bancorp DE grew its position in shares of MEDNAX by 38.5% in the second quarter. US Bancorp DE now owns 5,657 shares of the companys stock valued at $142,000 after purchasing an additional 1,572 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of MEDNAX in the fourth quarter valued at about $166,000. Finally, ETF Managers Group LLC grew its position in shares of MEDNAX by 166.0% in the second quarter. ETF Managers Group LLC now owns 6,845 shares of the companys stock valued at $168,000 after purchasing an additional 4,272 shares during the period. Hedge funds and other institutional investors own 92.30% of the companys stock.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

See the article here:
MEDNAX (NYSE:MD) Lowered to Neutral at Citigroup - Riverton Roll